# Lidocaine Intravenous in the Emergency Department For Sickle Cell Crisis

> **NCT04614610** · PHASE2 · UNKNOWN · sponsor: **Community Medical Center, Toms River, NJ** · enrollment: 100 (estimated)

## Conditions studied

- Sickle Cell Disease
- Sickle Cell Crisis
- Pain, Acute

## Interventions

- **DRUG:** Lidocaine Iv
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04614610
- **Lead sponsor:** Community Medical Center, Toms River, NJ
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-01-01
- **Primary completion:** 2025-01-02
- **Final completion:** 2025-06-01
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2023-08-29

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04614610

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04614610, "Lidocaine Intravenous in the Emergency Department For Sickle Cell Crisis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04614610. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*